Iterum Therapeutics plc (ITRM)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iterum Therapeutics plc ("Iterum" or "the Company") (NASDAQ: ITRM). The investigation concerns whether Iterum and certain of its officers and/or directors have violated federal securities laws.
On July 1, 2021, Iterum issued a press release “announc[ing] that the Company received a letter from the U.S. Food and Drug Administration (‘FDA’) stating that, as part of their ongoing review of the Company’s New Drug Application (‘NDA’) for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments at this time.” The press release further stated that “[n]o details with respect to deficiencies were disclosed by the FDA in this notification and the letter further states that the notification does not reflect a final decision on the information under review.” On this news, Iterum’s stock price fell $0.87 per share, or 37.99%, to close at $1.42 per share on July 2, 2021.
If you are aware of any facts relating to this investigation, or purchased Iterum shares, you can review a copy of the complaint and sign the certification form. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.